Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oophorectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,303 result(s) found for: Oophorectomy. Displaying page 5 of 116.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004151-79 Sponsor Protocol Number: TRIO030 Start Date*: 2017-05-08
    Sponsor Name:Translational Research in Oncology (TRIO)
    Full Title: A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
    Medical condition: Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001769-26 Sponsor Protocol Number: MB02-C-02-17 Start Date*: 2017-11-30
    Sponsor Name:mAbxience Research SL
    Full Title: STELLA – A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Pac...
    Medical condition: Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015833 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016523-61 Sponsor Protocol Number: PJMR0062105 Start Date*: 2009-12-07
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's & St Thomas NHS Trust
    Full Title: 18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation
    Medical condition: Osteopenia Please note this is not a study to investigate the use of the IMP for the treatment of osteopenia but rather to validate a non-invasive imaging technique for measuring early changes in b...
    Disease: Version SOC Term Classification Code Term Level
    12 10049088 Osteopenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001849-13 Sponsor Protocol Number: 2013/cardio3 Start Date*: 2013-07-09
    Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology
    Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis
    Medical condition: idiopathic recurrent pericarditis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000638-35 Sponsor Protocol Number: CZOL446N2312 Start Date*: 2004-09-15
    Sponsor Name:Novartis Sverige AB
    Full Title: A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12...
    Medical condition: Postmenopausal Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002418-12 Sponsor Protocol Number: CFEM345D2407 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early brea...
    Medical condition: Bone loss attributed to cessation of ovarian estrogen production is common in postmenopausal women. In postmenopausal women with breast cancer, treatment with an aromatase inhibitor may further red...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005241-38 Sponsor Protocol Number: LX6171.1-201-AAMI Start Date*: 2007-11-12
    Sponsor Name:Lexicon Pharmaceuticals Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) ...
    Medical condition: Age-Associated Memory Impairment (AAMI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027175 Memory impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003078-41 Sponsor Protocol Number: MUC-2/16 Start Date*: 2018-11-23
    Sponsor Name:MUCOS Pharma CZ s.r.o.
    Full Title: Reduction of post-traumatic systemic inflammatory response by Phlogenzym® using total hip replacement as a model.
    Medical condition: Total hip replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003183-13 Sponsor Protocol Number: OLATRA Start Date*: 2018-05-25
    Sponsor Name:GEICO - Grupo Español de Investigación en Cáncer de Ovario
    Full Title: Phase-II study of olaparib as maintenance therapy after response to trabectedinpegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Medical condition: Ovarian Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002825-52 Sponsor Protocol Number: CRAD001A2401T Start Date*: 2014-04-03
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (s...
    Medical condition: Acute cellular rejection after kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002767-98 Sponsor Protocol Number: UCDCRC/19/01 Start Date*: 2020-05-28
    Sponsor Name:University College Dublin
    Full Title: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)
    Medical condition: Patients with Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004575-12 Sponsor Protocol Number: DOMEC Start Date*: 2019-07-05
    Sponsor Name:Leiden University Medical Center
    Full Title: DOMEC - phase II trial of Durvalumab (MEDI4736) and Olaparib in Metastatic/recurrent Endometrial Cancer, a DGOG trial.
    Medical condition: advanced endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004230-37 Sponsor Protocol Number: BCX7353-312 Start Date*: Information not available in EudraCT
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An open-label study to provide berotralstat access to subjects with type 1 and 2 hereditary angioedema who were previously enrolled in berotralstat studies
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001976-39 Sponsor Protocol Number: GORTEC-2018-02 Start Date*: 2018-12-14
    Sponsor Name:GORTEC
    Full Title: A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
    Medical condition: Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002687-65 Sponsor Protocol Number: 2317 Start Date*: 2019-04-18
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: The NUVOLA TRIAL: Neoadjuvant chemoteraphy in Unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study.
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001203-32 Sponsor Protocol Number: DEDALUS Start Date*: 2021-10-25
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable Non –small-cell lung carcino...
    Medical condition: stage III unresectable non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000617-20 Sponsor Protocol Number: MITO31 Start Date*: 2018-11-14
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 transalational study.
    Medical condition: patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004758-39 Sponsor Protocol Number: ESR-18-13485 Start Date*: 2019-06-12
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER
    Medical condition: Locally advanced (T3-4 N0-1) rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002855-12 Sponsor Protocol Number: RM-493-034 Start Date*: 2022-04-22
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Rece...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:19:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA